跳至主要内容
临床试验/NCT00686608
NCT00686608已完成2 期

Hypothalamic fMRI Response to Nutrients

Oregon Health and Science University1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2006年10月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
56
试验地点
1
主要终点
The primary outcomes of this aim will be the change in fMRI response in the hypothalamus to IV glucose, to IV glucose during intralipid infusion, and to the IV glucose alone, in the lean and obese groups separately.

研究概览

简要总结

The purpose of this study is to identify how certain parts of the brain that control appetite respond to changes in dietary carbohydrate and fat.

详细描述

To measure fMRI signal change in hypothalamic and brainstem centers associated with control of food intake and energy expenditure in response to IV glucose, fructose, and saline. The fMRI response to these nutrients will then be compared in obese vs. lean subjects. Frequently timed blood samples will be obtained for measurement of nutrients (i.e., glucose) and blood levels of other factors (i.e., insulin, ghrelin, lactate) during these infusion protocols, and to test associations between these levels and the fMRI response.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Age 18 year to 45 years of age
  • •BMI 18 to 25 kg/m2 (25 subjects) and 30 to 40 kg/m2 (25 subjects), matched for age and sex.
  • •At maximal lifetime weight.
  • •Weight stable for at least 3 months.

排除标准

  • •Those with a major medical illness or who require prescription medication, including: cancer, coronary artery disease, hypertension, and diabetes.
  • •Subjects taking psychiatric or centrally-acting (CNS) medications, or who are diagnosed with a psychiatric or neurological illness, including: depression, anorexia, bulimia, and seizure disorder.
  • •Subjects who have lost weight as a result of dieting, pharmacological treatment, or bariatric surgery.
  • •Weight > 350 lbs or girth > 60 inches (the limits of the MR machine)
  • •Exercise > 30 minutes, 3 times a week.
  • •Alcohol consumption > 2 drinks / day.
  • •Weight > 300 lbs (150 kg) (weight limit for MR machine).
  • •Blood glucose > 100 mg/dL, abnormal creatinine or liver function tests.
  • •Illicit drug use.
  • •Pregnancy.
  • •Extreme dietary habits as determined by a GCRC nutritionist: very high or low dietary carbohydrate, protein, or fat intakes.
  • •Those with a contraindication to exposure to strong magnetic fields: presence of metal in the body such as body piercing, shrapnel, cardiac pacemakers or aneurysm clips.
  • •Those with claustrophobia.

研究组 & 干预措施

Saline

Placebo Comparator

干预措施: saline (Dietary Supplement)

Fructose

Active Comparator

干预措施: fructose (Dietary Supplement)

Glucose

Experimental

IV glucose

干预措施: glucose (Dietary Supplement)

结局指标

主要结局

The primary outcomes of this aim will be the change in fMRI response in the hypothalamus to IV glucose, to IV glucose during intralipid infusion, and to the IV glucose alone, in the lean and obese groups separately.

时间窗: 0,1,2 and 3 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jonathan Purnell

Principal Investigator

Oregon Health and Science University

研究点 (1)

Loading locations...

相似试验